Genmab A/S (OTCMKTS:GNMSF) Rating Increased to Buy at Zacks Investment Research

Share on StockTwits

Genmab A/S (OTCMKTS:GNMSF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. The firm presently has a $202.00 price objective on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 13.59% from the stock’s current price.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Genmab A/S stock opened at $177.84 on Wednesday. The company has a 50 day moving average of $177.76. The stock has a market cap of $10.90 billion, a P/E ratio of 55.40 and a beta of 0.16. Genmab A/S has a 1 year low of $119.10 and a 1 year high of $186.30.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Recommended Story: What are benefits of a growth and income fund?

Get a free copy of the Zacks research report on Genmab A/S (GNMSF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

TD Ameritrade  Upgraded to “Hold” by ValuEngine
TD Ameritrade Upgraded to “Hold” by ValuEngine
Home Bancshares  Raised to Hold at Zacks Investment Research
Home Bancshares Raised to Hold at Zacks Investment Research
Howard Bancorp  Cut to Hold at Zacks Investment Research
Howard Bancorp Cut to Hold at Zacks Investment Research
Pacific Booker Minerals  Downgraded by ValuEngine to Hold
Pacific Booker Minerals Downgraded by ValuEngine to Hold
Amphastar Pharmaceuticals Inc  Insider Sells $134,350.65 in Stock
Amphastar Pharmaceuticals Inc Insider Sells $134,350.65 in Stock
Insider Selling: Lantheus Holdings Inc  Director Sells $138,048.26 in Stock
Insider Selling: Lantheus Holdings Inc Director Sells $138,048.26 in Stock


© 2006-2019 Ticker Report